The first description of pneumocysts is credited to Chagas' in 1909, who mistook them for trypanosomes in guineapig lungs. Carini reported similar structures in rat lungs infected with Trypanosoma cruzi. Subsequently Dr and Madame Delanoe in Paris found pneumocysts in sewer rats without trypanosomiasis and proposed the name Pneumocystis carinii in honour of the Brazilian Carini.' Although Chagas probably reported the first human case of pneumocystosis, its importance was not recognised until the second world war, when outbreaks of pneumonia occurred throughout Europe in malnourished children in overcrowded orphanages. 23 Histologically, the lungs of such patients showed considerable mononuclear cell interstitial infiltration and foamy vacuolated alveolar exudates. The condition was named interstitial plasma cell pneumonia. A definite association with P carinii infection was made in 1952. 4 Subsequently, pneumocystis pneumonia was diagnosed in infants with congenital immunodeficiency states. Epidemic pneumocystis pneumonia has virtually disappeared from Europe, but is still recognised in parts of the world where malnutrition and poverty prevail.' 2 5 Until recently pneumocystis pneumonia largely affected patients receiving immunosuppressive treatment and corticosteroids for cancer, organ transplantation, and other conditions. Reports from 1981 onwards, however, detailed the association between pneumocystis pneumonia, other opportunistic infections, and Kaposi's sarcoma in previously well homosexual men and drug abusers. 6 The acquired immune deficiency syndrome (AIDS) has caused intense interest in the medical and lay press. Recently, 169 cases of AIDS have been recorded in the United Kingdom, 762 in Europe, and 8495 in the United States (Communicable Disease Surveillance Center, 1985, unpublished), As pneumocystis pneumonia is by far the commonest opportunistic infection (85%) in AIDS, clinicians and micro-biologists will need to become familiar with the diagnosis and treatment of pneumocystosis.
The organism
The taxonomy of P carinii continues to cause debate. At times it has been considered both as a trypanosome and as a fungus, largely owing to its ability to take up silver stains. It is now generally held to be a sporozoan with a life cycle similar to that of Toxoplasma gondii. This conclusion is supported by its susceptibility to antiparasitic agents. Although there are minor antigenic differences between strains isolated from various animal sources, they would all appear to belong to a single species since the similarities are greater than the differences.
The life cycle remains incompletely understood. Nevertheless detailed morphological studies of infected human and animal lungs by light and electron microscopy have increased our knowledge in recent years.78 The parasite exists in both trophozoite and cystic forms within the lung. The trophozoites are pleomorphic and 1-4 ,um in diameter, staining well with Giemsa. In contrast, the cysts are 5-7 gm in diameter, possess a thick wall, and stain best with methenamine silver stain, which makes them readily identifiable in tissues, although they are often outnumbered by the trophozoite forms at certain stages of the infection. The thick walled cysts contain up to eight smaller bodies or sporozoites. These are thought to emerge and develop into trophozoites, which may or may not undergo binary fission before maturing and developing into cysts to repeat the life cycle. Electron microscopic studies have shown the cyst to undergo maturation with the liberation of trophozoites before collapse.9 The trophozoite possesses a nucleus but few cytoplasmic organelles, although tubular extensions of the surface cytoplasm, or filopodia, can be visualised.
Koch's postulates have yet to be fulfilled in relation to pneumocystis pneumonia. Isolation of the parasite from the human lung, first reported by Pifer and her colleagues,'" is not routinely possible. Various cell lines permit isolation of the parasite in tissue 561 562 culture. These include Vero, CEL, WI-38, MRC 5, and Chang liver cells.'0-'2 The most successful so far appears to be the use of the Vero cell line with minimal essential medium and 2% fetal bovine serum.'3 The ratio of organisms to cells appears to be critical, as do the conditions of incubation. An atmosphere of 5% oxygen and 10% carbon dioxide favours growth, which is often maximal within a few days. '4 There is a trend towards a greater predominance of cystic forms over the trophozoites with more prolonged incubation. More recently P carinii has been cultivated in cell lines derived from lung. '5 The ready isolation of the parasite from the human lung would undoubtedly facilitate diagnosis and allow cultivation of large numbers of cysts and trophozoites. This in turn would lead to a greater understanding of the parasite, its antigenic determinants, and factors governing its various stages of growth.
Pathogenesis P carinii has been found to exist saprophytically in the lungs of a wide range of animal species, including man.'6 There is evidence to suggest that it is frequently acquired in early childhood, where it usually causes inapparent infections, coinciding with loss of maternally acquired antibody.'7 18 Infection presumably occurs by inhalation, although in view of the reports of congenital infection transplacental infection cannot be excluded.'9 It probably remains in a latent state for many years and undergoes reactivation in response to immune suppression, although case clustering has raised the possibility of hospital acquired infection. 20 There appear to be several differences between 563 pneumocystis pneumonia in AIDS patients and the condition affecting other immunosuppressed adults.37 39-1 One likely explanation for this may be that, unlike AIDS, immunosuppression in non-AIDS patient may often be modified both during and after pneumocystis pneumonia. The attack rate of 35-60% is high in AIDS. Symptoms appear to develop much more insiduously, over four weeks or so, although increased awareness of the condition may result in earlier presentation and diagnosis.39 Fevers, dyspnoea, dry cough, weight loss, diarrhoea, and malaise are common. Chest signs are sparse or absent. Pneumocystis pneumonia has, however, been diagnosed in both symptom free patients with abnormal chest radiographs39 and patients with mild symptoms who have normal radiographs.25 42 43 Patients with AIDS and pneumocystis pneumonia improve more slowly than others and the mortality rate is higher.37
Laboratory investigations
There are no haematological and biochemical tests that are helpful in diagnosing pneumocystis pneumonia. Abnormalities often result from the underlying disease or as a result of its treatment. Arterial blood gas estimations usually show severe hypoxia; arterial oxygen tensions (Pao2) of 8 kPa (60 mm Hg) or less are common.3942 Hypercapnia and respiratory acidosis occur at a late stage. Serial lung function testing in patients with AIDS and pneumocystis pneumonia shows progressive reduction in total lung capacity and vital capacity and a rise in the alveolar-arterial partial pressure gradient for oxygen. A reduction in diffusing capacity for carbon monoxide (TLCO) to less than 70% of the predicted value is reported in nearly all cases.254244
Radiographic findings
The typical radiographic finding is diffuse, bilateral alveolar and interstitial shadowing, beginning in the perihilar region and later coalescing and spreading into a butterfly pattern with relative sparing of lung apices and bases. Initially the shadowing is reticulonodular but progresses over three to If pneumocystis pneumonia is suspected in a patient with AIDS who has normal chest radiograph, it is recommended that invasive tests should be considered if any of the following are abnormal: gallium scan, TLco, or alveolar-arterial oxygen gradient. 25 We do not yet know whether any of these tests will be a useful screening procedure for patients with AIDS. Precautions to be taken when a patient with AIDS is being investigated by bronchoscopy have been reviewed elsewhere.2554 The success rate for diagnosing pneumocystis pneumonia at bronchoscopy is probably marginally lower in those who do not have AIDS,38 perhaps because of a lower pathogen burden in the lungs. Bronchoalveolar lavage, however, has been used successfully in immunosuppressed adults to diagnose pneumocystis pneumonia.40 55 56 The diagnostic problem is somewhat different in patients without AIDS because of the diversity of infective and non-infective pulmonary disease that may be present, and open lung biopsy is favoured by groups who have had extensive experience of diagnosing pneumocystis pneumonia. In Another approach to the serodiagnosis of pneumocystis pneumonia is antigen detection. This had considerable appeal since a host response to infection is not required. Pifer et all7 used countercurrent immunoelectrophoresis (CIE) to detect P 565 carinii antigen, with rabbit antiserum against P carinii isolated in tissue culture from human and murine lung. They found that 95% of patients with cancer who had pneumocystis pneumonia were antigenaemic, compared with 15% of cancer patients without pneumonitis and none of the normal children tested. Thus positive tests for antigen do not always indicate active disease but may reflect antigen mobilisation for other reasons. Nevertheless, clearance of antigenaemia does correlate well with clinical improvement." Fractionated P carinii antigens may improve specificity.69 In the future more sensitive antigen detection systems, such as radioimmunoassay and ELISA,70 are likely to make the diagnosis of pneumocystis pneumonia simple, rapid, and reliable through the examination of serum, lavage material, or possibly urine.
Management GENERAL MEASURES
The commonest complication of pneumocystis pneumonia is respiratory failure. This may require oxygen treatment and in some instances assisted ventilation. The need for assisted ventilation is associated with a poor prognosis. Of 102 patients with AIDS who required assisted ventilation, only 14% survived. 25 In patients having immunosuppressive treatment the aim should be to improve the immunocompetence of the individual by reducing immunosuppressive treatment or control of the underlying disease. The fact that at present the immunocompetence of patients with AIDS cannot be improved may explain the higher mortality rate in this group. Some clinicians favour the introduction, or an increased dosage, of corticosteroids to reduce the inflammatory response to pneumocystis pneumonia; but the fact that the condition is frequently associated with other opportunistic infections is probably the biggest argument against reintroduction of corticosteroids in such patients. Anecdotal reports suggest that lung lavage may be beneficial in removing some of the alveolar exudate and improving oxygenation (analogous to the management of alveolar proteinosis).38 SPECIFIC 
TREATMENT
The initial observation in 1958 that pentamidine was effective in the treatment of pneumocystis pneumonia in infants with the epidemic form of the disease was a major breakthrough." Pentamidine is an aromatic diamidino compound synthesised some 50 years ago and used in the treatment of African trypanosomiasis and resistant forms of leishmaniasis. Its efficacy in pneumocystis pneumonia was shown in a series of some 212 patients, in whom 566 the mortality fell from 50% in the untreated group to 3.5% in those receiving pentamidine isethionate. 72 The mode of action is not clear. One suggestion is that it interferes with folate metabolism,73 although folinic acid does not reduce its efficacy in experimental animal models. 74 The standard dosage regimen of pentamidine isethionate is 4 mg/kg a day for 14 days by the intramuscular route." Unfortunately toxicity is common, nephrotoxicity being recognised in almost a quarter of recipients,26 probably as a result of drug concentration within the kidney. 76 The list of other reported adverse reactions is impressive and includes hepatotoxicity with hypoglycaemia and occasionally liver necrosis, weakness, seizures, hypocalcaemia, nausea, vomiting, sweating, tachycardia, thrombocytopenia, and sterile abscesses at the injection site. Occasional deaths have been recorded. 75 Animal studies in 1966 indicated that antifolate agents such as pyrimethamine and sulphonamides were effective in pneumocystis pneumonia. 74 The subsequent availability of trimethoprim (TMP) led Hughes and his colleagues to conduct a successful study of the combination of trimethoprim and sulphamethoxazole (TMP-SMX) in the treatment of pneumocystis pneumonia in the rat model.77 TMP is concentrated in lung tissue and is less toxic to the marrow than pyrimethamine. Subsequent carefully executed trials showed the effectiveness of TMP-SMX in human pneumocystis pneumonia. 78 Response rates are similar to those with pentamidine79 but adverse reactions are largely avoided. TMP-SMX is known to inhibit nucleic acid synthesis through inhibition of the folic acid pathway. The sulphonamide inhibits the conversion of paraaminobenzoic acid to dihydrofolate, which in turn is blocked by TMP by its action on the enzyme dihydrofolate reductase. Neither pentamidine nor TMP-SMX is microbicidal-they are thought to act largely on the trophozoite form. The daily dose of TMP-SMX associated with optimal response rates consists of TMP 20 mg/kg plus SMX 100 mg/kg in three or four divided doses for a total of 14 days,79 although in patients with AIDS complicated by pneumocystis pneumonia more prolonged treatment is often necessary.47 Intravenous SMX-TMP is a useful alternative.808' The dose of TMP is 10-20 mg/kg/ day. The higher dose is often recommended initially, being reduced to 10-15 mg/kg a day when there is clinical improvement.
Although TMP-SMX is better tolerated than pentamidine it is not entirely without side effects. The most common complications are various rashes, which may occasionally be manifest as the StevensJohnson syndrome. Adverse reactions to high dose TMP-SMX are much more frequent in patients with AIDS.82 This is somewhat surprising owing to the overall anergy of this population and possibly argues against hypersensitivity as the basis for the reaction.
The use of TMP-SMX in renal failure may result in toxic blood levels. There is rather limited information available concerning dose modification.8384 Drug assay would appear desirable in these circumstances since it has been suggested that the therapeutic serum concentrations are 3-S5 mg/l for TMP and 100-150 mg/l for SMX two hours after oral administration.7
RESPONSE TO TREATMENT
The best guide to successful treatment is clinical improvement of the patient. Resolution is indicated by a fall in fever within one to five days and clearing of the chest radiograph within four to 10 days. Patients with AIDS take longer to improve. 39 Repeat lung function measurements44 and gallium scans43 do not appear to be helpful in monitoring response. Similarly, repeat lung biopsy or bronchoalveolar lavage not infrequently shows persistence of P carinii, even after two to three weeks of apparently effective treatment, particularly in patients with AIDS.254' 43 Clearance of P carinii and the inflammatory response appears faster in those without AIDS.4' In patients showing a poor response repeat bronchoscopy or lung biopsy may show a concurrent opportunistic infection. In survivors lung function abnormalities return to normal over a period of many weeks,44 although fibrosis has been reported. 38 In patients failing to respond to TMP-SMX by about the fifth day of treatment a change to pentamidine should be considered, particularly if there are signs of deterioration. Combined treatment with pentamidine and TMP-SMX has been considered in the hope of achieving either a synergistic effect or, by dose reduction, fewer side effects. In the cortisone treated rat model, however, this combination has not been shown to be more effective. 579293 The choice of diagnostic procedure will depend to a large extent on the expertise and facilities that are available locally, both in performing the various invasive techniques and also in handling the specimens in the laboratory. Close liason is essential between the clinician, surgeon, microbiologist, and cytohistopathologist. An urgent "out of hours" invasive technique is of little use if the specimens are not dealt with immediately in the laboratory by an experienced operator.
The future
In Britain, most clinicians' experience of pneumocystis pneumonia is very limited. It seems likely, however, that doctors other than oncologists and transplantation specialists will need to be aware of the presentation, diagnosis, and treatment of this infection. Clinicians will hope that further research will establish reliable serological methods for diagnosis by antigen and antibody detection, find practical ways of culturing human P cainii, and clarify the best method of diagnosing pneumocystis pneumonia at the earliest stage in susceptible individuals.
